Amgen Inc., et al. v. Sandoz Inc., et al.,
No. 14-cv-04741RS
On March 19, the Northern District of California became the
first court to interpret two key provisions of the Biological Price
Competition Act: whether biosimilar applicants must disclose their
applications to patentees and how far in advance they must provide
notice of their intent to enter the market.
The BPCIA, which was enacted as part of the Affordable Care Act,
provides an abbreviated FDA licensing application pathway for
producers of "biosimilars," biologic products that have
been shown to be substantially similar to a product that has
already been on the market for at least twelve years (so-called
"reference products"). Pursuant to the BPCIA, the
biosimilar's manufacturer may obtain FDA approval to sell its
product by relying on safety, purity, and potency data the
reference product's manufacturer (or "sponsor")
provided to the FDA when it sought approval for the reference
product. This